Literature DB >> 23032250

Psoriasis affects patient's quality of life more seriously in female than in male in Japan.

Tomotaka Mabuchi1, Hanako Yamaoka, Tomoko Kojima, Norihiro Ikoma, Emiko Akasaka, Akira Ozawa.   

Abstract

OBJECTIVE: The aim of this study was to assess the quality of life (QOL) of patients with psoriasis in Japan using Dermatology Life Quality Index (DLQI). Furthermore, we had evaluated the correlation between DLQI and clinical severity of psoriasis.
METHODS: The Japanese version of DLQI was used to assess the QOL of patients. Psoriasis area and severity index (PASI) and Itch visual analogue scale (VAS) were used to assess clinical severity of psoriasis.
RESULTS: The subjects were 102 Japanese patients with mild to severe psoriasis (77 males, 25 females, mean age 55.2 ± 14.2). There were no statistically significant differences in age, PASI, and itch VAS between male and female. The mean DLQI scores in total were 3.6 ± 3.2 in male and 7.2 ± 1.2 in female. The mean total DLQI scores in female were higher than that in male (p = 0.0016). Significant correlation was observed between DLQI scores and PASI score (p < 0.001) or itch VAS score (p < 0.001).
CONCLUSIONS: The mean total DLQI scores in female were significantly higher than that in male. Also, we confirmed the correlation between DLQI and clinical severity of psoriasis. These findings suggest that QOL assessment plays a greater role in females than in the males, when assessing the severity of psoriasis.

Entities:  

Mesh:

Year:  2012        PMID: 23032250

Source DB:  PubMed          Journal:  Tokai J Exp Clin Med        ISSN: 0385-0005


  12 in total

1.  The Burden on Cohabitants of Patients with Chronic Spontaneous Urticaria: A Cross-Sectional Study.

Authors:  Manuel Sánchez-Díaz; Maria-Carmen Salazar-Nievas; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

2.  Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.

Authors:  Emese Herédi; Fanni Rencz; Orsolya Balogh; László Gulácsi; Krisztina Herszényi; Péter Holló; Hajnalka Jókai; Sarolta Kárpáti; Márta Péntek; Éva Remenyik; Andrea Szegedi; Valentin Brodszky
Journal:  Eur J Health Econ       Date:  2014-05-16

3.  Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.

Authors:  Yoshinori Umezawa; Akihiko Asahina; Shinichi Imafuku; Yayoi Tada; Shigetoshi Sano; Akimichi Morita; Shinya Sakurai; Naoki Hoshii; Nicola Tilt; Hidemi Nakagawa
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-22

4.  Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.

Authors:  Yoshinori Umezawa; Shinya Sakurai; Naoki Hoshii; Hidemi Nakagawa
Journal:  Dermatol Ther (Heidelb)       Date:  2021-02-19

5.  Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis.

Authors:  George Gondo; Edward Hadeler; Nicholas Brownstone; Emanual Maverakis; Joseph F Merola; April W Armstrong; Tina Bhutani; Stacie J Bell; Wilson Liao
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-07

6.  Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: Analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study.

Authors:  Takuya Miyagi; Yasumasa Kanai; Kenta Murotani; Yukari Okubo; Masaru Honma; Satomi Kobayashi; Mariko Seishima; Yoko Mizutani; Hiroki Kitabayashi; Shinichi Imafuku
Journal:  JAAD Int       Date:  2022-06-22

7.  Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study.

Authors:  Joanna Emilio; Michelle Schwartz; Eleanor Feldman; Amy Kalowitz Bieber; Amanda Bienenfeld; Min-Kyung Jung; Daniel M Siegel; Orit Markowitz
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-04-20

8.  Acceptance of Illness, Satisfaction with Life, Sense of Stigmatization, and Quality of Life among People with Psoriasis: A Cross-Sectional Study.

Authors:  Beata Kowalewska; Mateusz Cybulski; Barbara Jankowiak; Elżbieta Krajewska-Kułak
Journal:  Dermatol Ther (Heidelb)       Date:  2020-03-19

9.  Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model.

Authors:  Kim A Papp; Ahmed M Soliman; Nicolae Done; Christopher Carley; Esteban Lemus Wirtz; Luis Puig
Journal:  Dermatol Ther (Heidelb)       Date:  2021-05-21

10.  Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan.

Authors:  Yukari Okubo; Ann Chuo Tang; Sachie Inoue; Hitoe Torisu-Itakura; Mamitaro Ohtsuki
Journal:  J Clin Med       Date:  2021-12-07       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.